Want to see AU:AHE full AI Analyst Report?
AHE Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.04
Previous CloseN/A
VolumeN/A
Average Volume (3M)286.73K
Market Cap
AU$9.57M
Enterprise Value-AU$1.74
Total Cash (Recent Filing)AU$9.53M
Total Debt (Recent Filing)AU$131.74K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding637,981,000
10 Day Avg. Volume116,165
30 Day Avg. Volume286,729
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-3.12
Price to Sales (P/S)0.22
P/FCF Ratio-0.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$112.30M
Bulls Say, Bears Say
Bulls Say
Integrated Healthcare Technology PlatformThe platform serves multiple participants in the medication ecosystem, linking pharmacy workflow, medication management, and digital engagement. This integrated positioning can support recurring relevance across healthcare workflows and create opportunities to serve pharmacies, patients, and pharmaceutical brands through connected offerings.
Debt ReductionMaterial debt reduction improves an important part of the capital structure and may reduce financing pressure relative to the prior year. Although negative equity remains a major constraint, lower debt can provide some incremental flexibility while management addresses the company’s broader financial weaknesses.
Prior Positive Cash GenerationPositive operating and free cash flow in 2024 demonstrates that the business has previously been capable of converting operations into cash. The improvement was not sustained, so it is not evidence of current strength, but it identifies a historical operating outcome that could be relevant to recovery efforts.
Bears Say
Persistent Revenue DeclineRepeated revenue declines indicate weakening top-line momentum and make it harder for the company to absorb fixed costs or fund product development. Continued contraction also limits the benefits of the healthcare technology platform and reduces the base from which any future operating recovery must occur.
Deep And Volatile LossesNegative gross profit and substantial operating and net losses show that the current revenue base is not supporting sustainable economics. This weak profitability can consume financial resources, restrict reinvestment, and leave results highly dependent on a successful improvement in margins and operating execution.
Negative Equity And Ongoing Cash BurnNegative equity combined with recurring operating and free-cash-flow deficits signals limited financial resilience. Ongoing cash burn can constrain investment in the platform and increase dependence on balance-sheet actions, while the negative equity base raises solvency concerns even after debt reduction.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$9.57M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Mar 04, 2027 which is in 167 days.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Aug 30, 2026. The company reported -AU$0.043 earnings per share for the quarter.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 637,981,000 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of -AU$0.043 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-58.36%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MedAdvisor Limited
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
PharmX Technologies
―
Alcidion Group Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―